News Breaks |
|
|
| April 26, 2010 |
| 10:54 EDT |  | WPI, PFE, MYL, FRX, TEVA | Pfizer may obtain compensation from Teva following court verdict
A federal court jury found on Friday that Pfizer's (PFE) patent for a drug known as Protonix is valid. Generic versions of Protonix, which are currently made by Israel's Teva (TEVA), India's Sun Pharma, and a company called Prasco, are used to treat ulcers. Most of the worldwide revenue from the generic version of the drug is currently obtained by Teva. In a note to investors, Cowen analysts predicted that Teva would have to pay compensation of about $400M to Pfizer. Teva was not willfully infringing the patent, since it had received a favorable preliminary injunction on the matter, and consequently would not be liable for triple damages, Cowen contends. The firm recommends that investors buy Teva on weakness today. Meanwhile, Citigroup analysts predict that the court would force Teva to pay about $652M in damages to Pfizer, but the firm predicts that such a verdict would reduce the Israeli company's 2010 profits by only $350M. However, the firm, which reiterates a Buy rating on Teva and a Hold rating on Pfizer, expects the companies to settle the matter out of court. On the other hand, Teva added that the judge could overturn the jury's verdict and invalidate Pfizer's patent. In mid-morning trading, Teva lost 1.10, or 1.78%, to $60.44, while Pfizer inched up 2c to $16.93. |
|
|
News For PFE;TEVA;MYL;WPI;FRX From The Last 14 Days Check below for free stories on PFE;TEVA;MYL;WPI;FRX the last two weeks. |
|
|
| May 21, 2013 |
| 07:35 EDT | | MYL | Mylan: Appellate Court rules in favor of company in patent infringement case
 Subscribe for More Information |
|
| 07:16 EDT |  | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| 11:27 EDT | | MYL, TEVA | Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva
Subscribe for More Information |
|
| 07:28 EDT | | FRX | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| 07:27 EDT | | FRX | American Psychiatric Association to host annual meeting
Subscribe for More Information |
|
| May 17, 2013 |
| 14:48 EDT |  | MYL | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information |
|
| 13:56 EDT | | MYL | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. |
|
| 10:36 EDT | | FRX | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| 07:31 EDT | | MYL | Mylan launches generic Tricor tablets
Subscribe for More Information |
| |
| May 16, 2013 |
| 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| May 15, 2013 |
| 19:37 EDT | | MYL | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information |
|
| 17:36 EDT | | MYL | Paulson gives quarterly update on stakes
Subscribe for More Information |
|
| 11:42 EDT | | MYL | Mylan launches generic Zomig tablets
Subscribe for More Information |
|
| 07:03 EDT |  | MYL | Mylan highly unlikely to acquire Actavis, says Barclays
Subscribe for More Information |
|
| May 14, 2013 |
| 13:55 EDT | | MYL | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information |
|
| 13:22 EDT | | MYL | Actavis turned down $15B takeover bid from Mylan, Bloomberg reports
Subscribe for More Information |
|
| May 13, 2013 |
| 09:44 EDT | | TEVA | Several companies reportedly interested in buying Adcock Ingram, Globes says
Subscribe for More Information |
|
| 07:49 EDT | | TEVA | FDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. |
|
| May 10, 2013 |
| 16:29 EDT |  | PFE | On The Fly: Closing Wrap
Subscribe for More Information |
| |
|
|
|
|
